Patel Naimish bought CRSP
April 3, 2025 · Form 4 insider transaction
Patel Naimish bought 1,508 shares of CRISPR Therapeutics AG at $32.96 per share, a transaction worth $49.7K. The trade was recorded as open-market purchase and disclosed on an SEC Form 4, filed 299 days after the transaction.
Footnotes
The purchase of Common Shares reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 1,508 shares, with a subsequent sale of Common Shares at a price of $35.94 per share on May 29, 2025 pursuant to a mandatory "sell to cover" provision in an award agreement covering a restricted stock unit that vested on such date (and which was reported on a separate Form 4 filing dated May 30, 2025). The Reporting Person has agreed to pay to the Issuer $4,493.84, representing the full amount of the profit realized in connection with the short-swing transaction.